2021
Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology
Karpin J, Rodriguez T, Traboulsi C, Rai V, Gibbons R, Rubin D. Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology. Crohn's & Colitis 360 2021, 3: otaa095. PMID: 34746788, PMCID: PMC8570563, DOI: 10.1093/crocol/otaa095.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseExact testActive inflammatory bowel diseaseClinical remission statusNegative CRP valuesMental health screeningPearson's chi-square testFisher's exact testMental health conditionsChi-square testCAT-MHIBD clinicIBD patientsPositive CRPUndiagnosed anxietyClinical remissionDisease activityIBD populationPatient characteristicsConsecutive patientsCRP valuesMultivariable analysisSignificant positive associationRemission status
2020
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease
Ollech J, Normatov I, Peleg N, Wang J, Patel S, Rai V, Yi Y, Singer J, Dalal S, Sakuraba A, Cohen R, Rubin D, Pekow J. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease. Clinical Gastroenterology And Hepatology 2020, 19: 104-110. PMID: 32109634, PMCID: PMC8665415, DOI: 10.1016/j.cgh.2020.02.035.Peer-Reviewed Original ResearchConceptsC-reactive proteinCrohn's diseaseFecal calprotectinInterval shorteningDisease activityStandard doseDose intervalMedian levelsLevels of CRPHarvey-Bradshaw Index scoreUstekinumab dose escalationSubset of patientsEndoscopic remissionClinical remissionEndoscopic evidenceDose escalationSingle centerRetrospective studyPatientsCalprotectinIndex scoreAbstractTextNormal levelsDiseaseWeeks
2019
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis
Ollech J, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer P, Christensen B, Pekow J, Dalal S, Sakuraba A, Cohen R, Rubin D. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019, 51: 637-643. PMID: 31875986, DOI: 10.1111/apt.15616.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedCalcineurin InhibitorsColitis, UlcerativeDrug Administration ScheduleDrug ResistanceFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexSteroidsTreatment OutcomeYoung AdultConceptsSevere steroid-refractory ulcerative colitisSteroid-refractory ulcerative colitisCalcineurin inhibitorsInduction therapyMaintenance therapyUlcerative colitisVedolizumab initiationMedian timeWeek 14Colectomy-free survival ratesSevere steroid-refractory colitisColectomy-free survivalSteroid-refractory colitisVedolizumab maintenance therapyInduction of remissionSerious adverse eventsSevere ulcerative colitisRetrospective observational studyEnd of inductionBiochemical remissionVedolizumab discontinuationClinical remissionPrimary endpointSecondary endpointsAdult patients